A phase Ib, randomised, double-blind, placebo-controlled, multiple-dose escalation study evaluating the safety, tolerability and pharmacokinetics of NSI-189 in patients with major depressive disorder.

Trial Profile

A phase Ib, randomised, double-blind, placebo-controlled, multiple-dose escalation study evaluating the safety, tolerability and pharmacokinetics of NSI-189 in patients with major depressive disorder.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2016

At a glance

  • Drugs NSI 189 (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions
  • Sponsors Neuralstem
  • Most Recent Events

    • 12 May 2016 Results published in a Neuralstem media release.
    • 08 Dec 2015 Results of this trial were published in Molecular Psychiatry, according to a Neuralstem media release.
    • 08 Dec 2015 Results published in a Neuralstem media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top